drugset / Trial / NCT00054808

Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00054808

Phase 2 Completed 40 enrolled Genta Incorporated
Non-randomizedOpen-labelTreatment

Summary

Eligible patients will have low- or intermediate-grade Non-Hodgkin's Lymphoma (NHL) that has progressed after standard chemotherapy. Patients will receive gallium nitrate 300 mg/m2/day by continuous IV infusion for 7 consecutive days using a portable infusion pump. Hospitalization is not required. Stable or responding patients will receive additional gallium nitrate infusions every 3 weeks until the time of disease progression, for a maximum total of 8 infusions, or 2 cycles after complete remission has been documented.

Timeline

Start
2002-06
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject gallium nitrate Small molecule 300 mg/m2 Intravenous

Indications